Impulse control disorders in Parkinson's disease: definition, epidemiology, risk factors, neurobiology and management

Parkinsonism and Related Disorders

Volumn 15, Issue SUPPL. 4, 2009, Pages

  Ceravolo, Roberto ^a   Frosini, Daniela ^a   Rossi, Carlo ^a   Bonuccelli, Ubaldo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Dopamine receptor agonists; Impulse control disorders; Parkinson's disease

Indexed keywords

APOMORPHINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOT DERIVATIVE; LEVODOPA; LITHIUM; NALMEFENE; NEUROLEPTIC AGENT; OLANZAPINE; PERGOLIDE; PRAMIPEXOLE; PSYCHOTROPIC AGENT; QUETIAPINE; RACLOPRIDE; RISPERIDONE; ROPINIROLE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; VALPROIC ACID;

AGE; ARTICLE; CLINICAL TRIAL; COMPULSION; DIAGNOSTIC TEST; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EATING DISORDER; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENDER; HUMAN; HYPERSENSITIVITY; HYPERSEXUALITY; IMPULSE CONTROL DISORDER; IMPULSIVENESS; LOW DRUG DOSE; MONOTHERAPY; MOTOR DYSFUNCTION; NEUROBIOLOGY; NEUROTOXICITY; OBSESSIVE COMPULSIVE DISORDER; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PATHOPHYSIOLOGY; PATIENT CARE; PERSONALITY; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RESTLESS LEGS SYNDROME; RISK ASSESSMENT; RISK FACTOR; SYMPTOM; ANIMAL; DISEASE MANAGEMENT; IMPULSE CONTROL DISORDERS;

ANIMALS; DISEASE MANAGEMENT; HUMANS; IMPULSE CONTROL DISORDERS; PARKINSON DISEASE; RISK FACTORS;

EID: 72649103551     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(09)70847-8     Document Type: Article

References (50)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fourth edition, text revision (2000), American Psychiatric Association, Washington, DC
2. Evans A.H., Katzenschlager R., Paviour D., O'Sullivan J.D., Appel S., Lawrence A.D., et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 19 (2004) 397-405
3. Weintraub D. Dopamine and impulse control disorders in Parkinson's disease. Ann Neurol 64 Suppl 2 (2008) S93-100
4. Giovannoni G., O'Sullivan J.D., Turner K., Manson A.J., and Lees A.J. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 68 (2000) 423-428
5. Holden C. "Behavioral" addictions: do they exist?. Science 294 (2001) 980-982
6. Tamminga C.A., and Nestler E.J. Pathological gambling: focusing on the addiction, not the activity. Am J Psychiatry 163 (2006) 180-181
7. Brewer J.A., and Potenza M.N. The neurobiology and genetics of impulse control disorders: relationships to drug addictions. Biochem Pharmacol 75 (2008) 63-75
8. Hollander E., and Allen A. Is compulsive buying a real disorder, and is it really compulsive?. Am J Psychiatry 163 (2006) 1670-1672
9. Driver-Dunckley E., Samanta J., and Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 61 (2003) 422-423
10. Lu C., Bharmal A., and Suchowersky O. Gambling and Parkinson disease. Arch Neurol 63 (2006) 298
11. Grosset K.A., Macphee G., Pal G., Stewart D., Watt A., Davie J., et al. Problematic gambling on dopamine agonists: not such a rarity. Mov Disord 21 (2006) 2206-2208
12. Voon V., Hassan K., Zurowski M., Duff-Canning S., de Souza M., Fox S., et al. Prospective prevalence of pathological gambling and medication association in Parkinson disease. Neurology 66 (2006) 1750-1752
13. Weintraub D., Siderowf A.D., Potenza M.N., Goveas J., Morales K.H., Duda J.E., et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 63 (2006) 969-973
14. Voon V., Hassan K., Zurowski M., de Souza M., Thomsen T., Fox S., et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 67 (2006) 1254-1257
15. Isaias I.U., Siri C., Cilia R., De Gaspari D., Pezzoli G., and Antonini A. The relationship between impulsivity and impulse control disorders in Parkinson's disease. Mov Disord 23 (2008) 411-415
16. Christenson G.A., Faber R.J., deZwaan M., Raymond N.C., Specker S.M., Ekern M.D., et al. Compulsive buying: descriptive characteristics and psychiatric comorbidity. J Clin Psychiatry 55 (1994) 5-11
17. Crockford D., Quickfall J., Currie S., Furtado S., Suchowersky O., and El-Guebaly N. Prevalence of problem and pathological gambling in Parkinson's disease. J Gambl Stud 24 (2008) 411-422
18. Avanzi M., Baratti M., Cabrini S., Uber E., Brighetti G., and Bonfà F. Prevalence of pathological gambling in patients with Parkinson's disease. Mov Disord 21 (2006) 2068-2072
19. Ceravolo R., Frosini D., Rossi C., Nicoletti V., Berti C., Unti E., et al. Prevalence of impulse control disorders in Parkinson's disease. Neurol Sci 30 Suppl (2009) 456
20. Vogel H.P., and Shiffter R. Hypersexuality-a complication of dopaminergic therapy in Parkinson's disease. Pharmacopsychiatria 16 (1983) 107-110
21. Harvey N.S. Serial cognitive profiles in levodopa-induced hypersexuality. Br J Psychiatry 153 (1988) 833-836
22. Uitti R.J., Tanner C.M., Rajput A.H., Goetz C.G., Klawans H.L., and Thiessen B. Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol 12 (1989) 375-383
23. O'Sullivan J.D., and Hughes A.J. Apomorphine-induced penile erections in Parkinson's disease. Mov Disord 13 (1998) 536-539
24. Klos K.J., Bower J.H., Josephs K.A., Matsumoto J.Y., and Ahlskog J.E. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 11 (2005) 381-386
25. Gallagher D.A., O'Sullivan S.S., Evans A.H., Lees A.J., and Schrag A. Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord 22 (2007) 1757-1763
26. Evans A.H., Lawrence A.D., Potts J., Appel S., and Lees A.J. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology 65 (2005) 1570-1574
27. Giladi N., Weitzman N., Schreiber S., Shabtai H., and Peretz C. New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson's disease: the role of dopamine agonist treatment and age at motor symptoms onset. J Psychopharmacol 21 (2007) 501-506
28. Singh A., Kandimala G., Dewey Jr. R.B., and O'Suilleabhain P. Risk factors for pathologic gambling and other compulsions among Parkinson's disease patients taking dopamine agonists. J Clin Neurosci 14 (2007) 1178-1181
29. Voon V., Thomsen T., Miyasaki J.M., deSouza M., Shafro A., Fox S.H., et al. Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol 64 (2007) 212-216
30. Pontone G., Williams J.R., Bassett S.S., and Marsh L. Clinical features associated with impulse control disorders in Parkinson disease. Neurology 67 (2006) 1258-1261
31. Santangelo G., Vitale C., Trojano L., Verde F., Grossi D., and Barone P. Cognitive dysfunctions and pathological gambling in patients with Parkinson's disease. Mov Disord 24 (2009) 899-905
32. Dodd M.L., Klos K.J., Bower J.H., Geda Y.E., Josephs K.A., and Ahlskog J.E. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 62 (2005) 1377-1381
33. Driver-Dunckley E.D., Noble B.N., Hentz J.G., Evidente V.G., Caviness J.N., Parish J., et al. Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol 30 (2007) 249-255
34. Blum K., Sheridan P.J., Wood R.C., Braverman E.R., Chen T.J., and Comings D.E. Dopamine D2 receptor gene variants: association and linkage studies in impulsiveaddictive-compulsive behaviour. Pharmacogenetics 5 (1995) 121-141
35. Comings D.E., Gonzalez N., Wu S., Gade R., Muhleman D., Saucier G., et al. Studies of the 48 bp repeat polymorphism of the DRD4 gene in impulsive, compulsive, addictive behaviors: Tourette syndrome, ADHD, pathological gambling, and substance abuse. Am J Med Genet 88 (1999) 358-368
36. Pérez de Castro I., Ibáñez A., Torres P., Sáiz-Ruiz J., and Fernández-Piqueras J. Genetic association study between pathological gambling and a functional DNA polymorphism at the D4 receptor gene. Pharmacogenetics 7 (1997) 345-348
37. Lee J.Y., Lee E.K., Park S.S., Lim J.Y., Kim H.J., Kim J.S., et al. Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson's disease. Mov Disord (2009 Jun 26) [Epub ahead of print]
38. Reuter J., Raedler T., Rose M., Hand I., Gläscher J., and Büchel C. Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat Neurosci 8 (2005) 147-148
39. Evans A.H., Pavese N., Lawrence A.D., Tai Y.F., Appel S., Doder M., et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 59 (2006) 852-858
40. Cilia R., Siri C., Marotta G., Isaias I.U., De Gaspari D., Canesi M., et al. Functional abnormalities underlying pathological gambling in Parkinson disease. Arch Neurol 65 (2008) 1604-1611
41. 11C] raclopride PET study. Brain 132 (2009) 1376-1385
42. Mamikonyan E., Siderowf A.D., Duda J.E., Potenza M.N., Horn S., Stern M.B., et al. Long-term follow-up of impulse control disorders in Parkinson's disease. Mov Disord 23 (2008) 75-80
43. Ardouin C., Voon V., Worbe Y., Abouazar N., Czernecki V., Hosseini H., et al. Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord 21 (2006) 1941-1946
44. Kurlan R. Disabling repetitive behaviors in Parkinson's disease. Mov Disord 19 (2004) 433-437
45. Courty E., Durif F., Zenut M., Courty P., and Lavarenne J. Psychiatric and sexual disorders induced by apomorphine in Parkinson's disease. Clin Neuropharmacol 20 (1997) 140-147
46. Jiménez-Jiménez F.J., Sayed Y., García-Soldevilla M.A., and Barcenilla B. Possible zoophilia associated with dopaminergic therapy in Parkinson disease. Ann Pharmacother 36 (2002) 1178-1179
47. Gschwandtner U., Aston J., Renaud S., and Fuhr P. Pathologic gambling in patients with Parkinson's disease. Clin Neuropharmacol 24 (2001) 170-172
48. Grant J.E., and Potenza M.N. Impulse control disorders: clinical characteristics and pharmacological management. Ann Clin Psychiatry 16 (2004) 27-34
49. Klos K.J., Bower J.H., Josephs K.A., Matsumoto J.Y., and Ahlskog J.E. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 11 (2005) 381-386
50. Grant J.E., Potenza M.N., Hollander E., Cunningham-Williams R., Nurminen T., Smits G., et al. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry 163 (2006) 303-312